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Introduction
Pseudomonas aeruginosa is considered one of the 
most leading causes of healthcare associated infections 
(HCAIs) worldwide (Varaiya et al., 2008). It is consid-
ered the fourth most commonly isolated nosocomial 
pathogen accounting for 10% of all HCAIs. P. aeruginosa 
infections can range from superficial skin infections to 
fulminant sepsis. Even colonization of such strains in 
critical systems can be fatal (Sivaraj et al., 2012). 
World Health Organization (2015) has identified 
antimicrobial resistance as one of the three most impor-
tant problems for human health. P. aeruginosa represents 
a phenomenon of resistance since all known mecha-
nisms of antimicrobial resistance can be encountered; 
nevertheless enzyme production is the major mecha-
nism of acquired resistance in these strains especially 
with β-lactam antibiotics, which are considerd a major 
line of treatment for P. areuginosa. Of these enzymes are 
the β-lactamases (Strateva and Yordanov, 2009). There 
are four classes of β-lactamases: A, C and D which act 
through a serine based mechanism and metallo-beta-
lactamases (MBL); a class B type of β-lactamases that 
is the most worrisome and require bivalent metal ions, 
usually zinc as a cofactor for their activity (Bush and 
Jacopy, 2010). This group can be suppressed by biva-
lent ionic chelators as ethylene diamine tetra acetic acid 
(EDTA), but not inhibited by commercial β-lactamase 
inhibitors as clavulanic acid and tazobactam. They can 
hydrolyze β-lactams from all classes except the mono-
bactams (Aoki et al., 2010). 
MBL producing P. aeruginosa isolates were first 
reported in Japan in 1991, and since then there has 
been a substantial increase in the reporting of MBLs 
among carbapenem-resistant P. aeruginosa isolates 
worldwide (Pitout et al., 2005). These isolates increas-
ingly have been responsible for several nosocomial out-
breaks in tertiary centers in different parts of the world 
(Walsh, 2008). Also the association between infections 
caused by MBL producing P. aeruginosa and longer 
hospital stay with high mortality rates has been reported 
(Zavascki et al., 2006). 
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A b s t r a c t
Pseudomonas aeruginosa has emerged as a major healthcare associated pathogen that creates a serious public health disaster in both develop-
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The problem is aggravated by the fact that most of 
the MBL encoding genes reside on integrons and plas-
mids which in turn allows for widespread dissemina-
tion of these genetic elements, hence poses a threat for 
spread resistance patterns among the Gram-negative 
bacteria (Mohamed and Raafat, 2011).
As regards molecular structure: five MBL types have 
been widely recognized; imipenemase (IMP), Verona 
integron-encoded (VIM), Sao Paulo (SPM), German 
imipenemase (GIM) and Seoul imipenemase (SIM). 
Several types of MBL enzymes have been identified in 
P. aeruginosa among which the VIM-type enzymes appear 
to be the most prevalent. IMP is also considered one 
of the most important types of MBLs. Camagaro et al., 
(2011) reported that after being restricted for more than 
ten years to Brazilian hospitals; SPM seems to become 
a global challenge, warning for the role of human traffic 
in spreading MBL genes (Salabi et al., 2010). 
It is well known that poor outcome occurs when 
patients with serious infections due to MBL produc-
ing organisms are treated with antibiotics to which the 
organism is completely resistant. Therefore early and 
proper detection of MBL producing Gram-negative 
bacilli especially P. aeruginosa is crucial; for optimal 
treatment of particularly critically ill and hospitalized 
patients and to permit rapid initiation of strict infection 
control procedures to prevent nosocomial spread and 
control the dissemination of resistance (Cuzon et al., 
2012). This work aimed at studying the occurrence of 




This cross sectional study was carried out during an 
18-month period from January 2013 to June 2014. It 
included different clinical samples that were collected 
from patients admitted to the Alexandria University 
Students’ Hospital (AUSH). Collected clinical samples 
were processed in AUSH laboratory and the Microbi-
ology laboratory at the High Institute of Public Health 
(HIPH). The study was approved by the Ethics Com-
mittee of the HIPH. Informed consents of all enrolled 
patients were obtained before collection of samples 
and after explanation of the purpose and benefits of 
the research.
Sampling
Data collection. A questionnaire sheet including all 
the relevant information (name, age, sex, date of admis-
sion, medical history, diagnosis, antibiotic administra-
tion etc.) was filled in for every patient enrolled in the 
present study.
Samples collection and processing. A total of 1583 
different clinical samples were collected during the study 
period from patients showing signs and symptoms sug-
gestive of infection and were delivered to the laboratory. 
The samples were distributed as 660 respiratory sam-
ples (500 bronchoalveolar lavage (BAL) and 160 sputum 
samples), 446 urine samples, 209 blood samples, 142 
pus and exudate samples, 58 peritoneal fluid samples, 
35 ear discharge, and 33 conjunctival secretions. Col-
lected samples were subjected to macro scopical and 
microscopical examination. The samples were cultured 
on blood (Oxoid 9191118 UK) and MacConkey’s agar 
(Oxoid 567362 UK) plates. Plates were incubated aero-
bically at 37°C for 24 hours (Tille et al., 2014). 
Identification procedures of P. aeruginosa. After 
proper incubation of inoculated blood and MacCon-
key’s agar plates, isolates that appeared as medium 
sized, grayish, opaque, large flat pigmented colonies, 
with feathered edges, producing a sweet or grape like 
odour either hemolytic or non hemolytic on blood 
agar plates, and were pale, non lactose fermenting on 
MacConkey’s agar plates, and microscopically appeared 
as Gram-negative bacilli were further differentiated 
and identified according to standard microbiological 
methods (Tille et al., 2014). 
Antimicrobial susceptibility testing (AST). All 175 
confirmed P. aeruginosa isolates were tested for their 
antibiotic susceptibility patterns using single disc dif-
fusion method according to the Clinical and Labora-
tory Standards Institute (CLSI) recommendations (Patel 
et al., 2014). The test was done on Mueller Hinton (MH) 
agar plates (Difco 00252-01), using the selected antibio-
tic discs. All antimicrobial discs used in this study were 
supplied by oxoid laboratories. After 24 hours aerobic 
incubation at 37°C, each plate was examined and inhibi-
tion zones were measured, recorded, and interpreted as 
susceptible (S), intermediate (I) or resistant (R) accord-
ing to the interpretive criteria of CLSI (Patel et al., 2014). 
Isolates that were confirmed to be P. aeruginosa 
and tested for their antimicrobial susceptibility pat-
terns were then subcultured on blood agar plates and 
incubated aerobically at 37°C for 24 hrs. Isolated colo-
nies were inoculated on soft agar deeps and incubated 
aerobically at 37°C for 24 hrs. 
Identification of metallo beta lactamase produc-
tion by Epsilometer test (E-test). Thirty confirmed 
P. aeruginosa isolates were selected to be tested for 
their MBL enzyme production by E test. MBL diag-
nostic E-test strip consists of a double sided seven dilu-
tion range of imipenem (IP) (4 to 256 microgram/ml) 
and IP overlaid with EDTA (1 to 64 microgram/ml) 
(Pitout et al., 2005). MBL E-test was performed accord-
ing to the manufacturer’s instructions (AB BioMerieux, 
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Solna, Sweden). Isolates stored in agar deeps were 
subcultured on blood agar plates and were incubated 
aerobically at 37°C for 24 hrs. Individual colonies were 
picked from overnight agar plates and suspended 
in a 0.85% saline and were adjusted to a turbidity of 
0.5 McFarland standard.
E-test MBL strips were applied to MH agar plates 
inoculated with adjusted suspensions. Seeded MH agar 
plates were incubated aerobically for 24 hrs at 37°C.The 
minimum inhibitory concentration (MIC) end points 
were read where the inhibition ellipses intersected the 
strip. A reduction of imipenem MIC in the presence 
of EDTA that is greater than or equal to eight-fold 
(IP/IPI > 8 mm) was interpreted as indicating MBL 
activity. The presence of a phantom zone or a defor-
mation of the imipenem ellipse was also considered 
a positive result (Pitout et al., 2005). 
Detection of blaIMP, blaVIM, and blaSPM MBL genes 
by PCR. Thirty P. aeruginosa isolates that were con-
firmed as MBL producers by MBL diagnostic E-test, 
were tested for the presence of blaIMP, blaVIM, blaSPM genes.
DNA extraction
Procedure. DNA for PCR was extracted by the boil-
ing method. Two or three colonies were taken from 
fresh culture of the confirmed MBL P. aeruginosa iso-
lates and suspended in 500 μl saline, then vortexed to 
get a uniform suspension. The cells were lysed by heat-
ing them at 100°C for 10 minutes, and then centrifuged 
at 12,000 rpm for 10 min. The supernatant was used 
directly as a template DNA in the PCR mixture.
DNA amplification. The extracted DNA was sub jec-
ted to PCR amplification reaction using three pairs of 
primers specific for MBL genes (blaIMP, blaVIM, and blaSPM). 
The DNA amplification was done using Dream Taq 
Green PCR Master mix (Thermo Scientific, Waltham, 
United States). The primers were purchased lyophi-
lized; (Biosearch Tech, Petaluma, California, United 
States). They were reconstituted by the addition of sterile 
nuclease free water to a final concentration of 100 pico 
mol/μl, distributed in aliquots and stored at –20°C.
Primers sequence of MBL genes (Sader et al., 2005)
b-PCR amplification protocol. (I) Reaction mix-
tures were prepared using sterile nuclease free water. 
To each tube a total volume of 50 ml was reached by 
adding Master mix (25 μl), sense primer (1 μl), anti-
sense primer (1 μl), DNA template (sample) (10 μl), 
nuclease free water (13 μl). A negative control was pre-
pared by the addition of the same contents to the tube 
with 10 μl nuclease free water instead of the sample.
(II) The tubes were transferred to the thermal cycler 
(BioCycler TC-S, Boeco-Germany) for amplification. 
The thermocycler program conditions for blaIMP and 
blaVIM genes included: 30 cycles of amplification under 
the following conditions: denaturation at 95°C for 
30 seconds, annealing for 1 minute at specific tempera-
tures (blaIMP at 45°C and blaVIM–66°C), and extension at 
72°C for 1 minutes/kb product (Khosravi et al., 2011). 
The cycling parameters of PCR to amplify blaSPM gene 
were: initial denaturation at 95°C for 5 min, followed by 
30 cycles of denaturation at 95°C for 1 min, annealing at 
50°C for 1 minute and extension at 68°C for 1 minute. 
The cycle was followed by a final extension at 72°C for 
10 minutes (Gaspareto et al., 2007). 
DNA detection by gel electrophoresis. PCR pro-
ducts were loaded on 2% agarose in tris borate EDTA 
(TBE) containing 0.5 μl of ethidium bromide per ml. 
After electrophoresis, the gel was visualized under 
ultraviolet light.
The DNA bands were visualized on a 320 nm UV 
transilluminator and photographed. The gel was exam-
ined for specific bands; positive results of PCR were 
confirmed by detection of 432 bp band for blaIMP gene, 
500 bp band for blaVIM gene and 650 bp band for blaSPM 
gene as determined by the molecular weight markers 
run at the same time. (Khosravi et al., 2011; Gaspareto 
et al., 2007).
Statistical analysis of the data. Data were fed to 
the computer and analyzed using IBM SPSS software 
package version 20.0 (Kirkpatrick and Feeney, 2013). 
Qualitative data were described using number and 
percent. Quantitative data were described using Range 
(minimum and maximum), mean, standard deviation 
and median. Comparison between different groups 
regarding categorical variables was tested using Chi-
square test, Fisher’s exact test, Monte Carlo correction, 
independent t-test and Mann Whitney test. Signifi-
cance of the obtained results was judged at the 5% level.
Results
The present study included 175 P. aeruginosa iso-
lates that were recovered from a total of 1583 clinical 
samples. These samples were collected randomly from 
patients admitted to the AUSH (984 from ICUs and 
599 from wards). 
The highest percentage of P. aeruginosa isolates 75 
(42.9%) were recovered from respiratory samples, fol-
lowed by urine samples 57 (32.6%) and pus and exudate 
IMP 1 Sense: 5’dCTACCGCAGCAGAGTCTTTGC3’
 Antisense: 5’dGAACAACCAGTTTTGCCTTACC3’
VIM 2 Sense: 5’dATGTTCAAACTTTTGAGTAGTAAG3’ 
 Antisense: 5’dCTACTCAACGACTGAGCG3’
SPM 1 Sense: 5dCCTACAATCTAACGGCGACC3’
 Antisense: 5’dTCGCCGTGTCCAGGTATAAC3’
Primer Sequence (5’ to 3’)
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samples 33 (18.9%). From blood samples, four P. aerugi­
nosa isolates were recovered (2.3%), while each of con-
junctival secretion, ear discharge, and peritoneal fluid 
samples yielded two P. aeruginosa isolates (1.1% each).
In the current work, the highest percentage of resist-
ance among 175 detected P. aeruginosa isolates was for 
aztreonam 150 (85.7%), followed by ceftazidime 140 
(80%), cefipime 139 (79.4%), imipenem 137 (78.3%), 
ciprofloxacin 134 (76.6%), and meropenem 129 (73.7%).
On the other hand, the highest susceptibility percen-
tages were recorded for polymyxin B 152 (86.9%), piper-
acillin tazobactam 52 (29.7%), 48 ofloxacin (27.4%), 
piperacillin 46 (26.3 %), gentamycin 39  (22.3%) and 
cefepime 28 (16%).
Of the 175 confirmed P. aeruginosa isolates, 30 iso-
lates were randomly selected to be tested phenotypi-
cally for their MBL enzyme production by E test. Thirty 
selected P. aeruginosa isolates were as follows:
•	Twenty	 P. aeruginosa isolates were resistant to 
three classes of β-lactams including: cephems, 
carba penems and monobactams (aztreonam).
•	Three P. aeruginosa isolates were resistant to three 
classes of β-lactams (penicillins, cephalospor-
ins and carbapenems) and were susceptible to 
aztreonam.
•	 Seven P. aeruginosa isolates were resistant to three 
classes of antibiotics (cephems, aminoglycosi-
des, and carbapenems), but were susceptible to 
imipenem, and 4 of them were also susceptible 
to meropenem.
This study showed that the highest percentage of 
MBL producing P. aeruginosa isolates were from respir-
atory samples 11/30 (36.7%), followed by urine, and pus 
and exudate samples 9/30 (30%) each. Only one isolate 
was recovered from an ear sample 1/30 (3.3%) (Fig. 1).
Thirty selected isolates were all positive for MBL 
production by MBL E test, and were tested for blaIMP, 
blaVIM and blaSPM genes using conventional PCR (results 
as in Fig. 2). Of the 30 tested isolates; 19 (63.3%) 
Fig. 1. Distribution of 30 MBL producing P. aeruginosa isolates
according to type of samples.
Fig. 2C blaVIM
Lane 1: Marker 100 bp Ladder 
Lane 2: Negative test strain for blaVIM (500 bp)
Lane 3: Negative test strain for blaVIM (500 bp)
Lane 4: Negative control 
Lane 5: Negative test strain for blaVIM (500 bp)
Lane 6: Negative test strain for blaVIM (500 bp)
Lane 7: Negative test strain for blaVIM (500 bp)
Lane 8: Negative test strain for blaVIM (500 bp)
Fig. 2. A, B, C. Electrophoresis results for P. aeruginosa blaIMP,
blaSPM and blaVIM genes.
Fig. 2A blaIMP
Lane 1: Marker 100 bp Ladder 
Lane 2: Positive test strain for blaIMP (432 bp)
Lane 3: Positive test strain for blaIMP (432 bp)
Lane 4: Positive test strain for blaIMP (432 bp)
Lane 5: Positive test strain for blaIMP (432 bp)
Lane 6: Negative control
Lane 7: Positive test strain for blaIMP (432 bp)
Fig. 2B blaSPM
Lane 1: Marker 100 bp Ladder 
Lane 2: Negative control
Lane 3: Positive test strain for blaSPM (650 bp)
Lane 4: Positive test strain for blaSPM (650 bp)
Lane 5: Positive test strain for blaSPM (650 bp)
Lane 6: Positive test strain for blaSPM (650 bp)
Lane 7: Positive test strain for blaSPM (650 bp)
Lane 8: Positive test strain for blaSPM (650 bp)
Lane 9: Positive test strain for blaSPM (650 bp)
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revealed blaSPM gene and 11(36.7%) had blaIMP gene, 
blaVIM gene was not detected in any of the tested isolates.
Of the 30 patients with MBL producing P. aerugi­
nosa isolates, 14(46.7%) were of age group 20 ≤ 30 years, 
9 (30.0%) belonged to the age group 30–50 years, and 
seven patients (23.3%) were above 50 years (Table I). 
Moreover, our data showed that the highest percent-
age of patients who revealed P. aeruginosa isolates with 
positive blaSPM gene were aged 20 ≤ 30 years old (47.4%), 
followed by those aged > 50 years old (31.6%). 
In this study the majority of patients with MBL 
producing P. aeruginosa isolates 21 (70%) were admit-
ted to the ICU and 9 (30%) were admitted in inpatient 
wards. In addition, the highest percentage (76.7%) was 
recovered from those who had duration of hospital stay 
of more than 7 days. Regarding antibiotic intake, the 
majority of patients 26/30 (86.7%) had taken antibiot-
ics within 2 weeks from the study period, and this was 
found to be statistically significant (p ≤ 0.001). On the 
other hand, 23/30 (76.7%) patients were readmitted 
to the hospital within 3 months. This was statistically 
significant (p ≤ 0.006) (Table II).
Our work revealed that the 30  MBL producing 
P. aeruginosa isolates were highly susceptible to poly-
mxin B 26 (86.7%), followed by piperacillin-tazobactam 
11 (36.7%), then gentamycin 8 (26.7%). Seven (23.3%) 
isolates were susceptible to each of imipenem and oflo-
xa cin. The highest percentage of isolates were resistant 
to Amikacin 26/30 (86.7%), followed by piperacillin 
and ciprofloxacin 24 /30(80% each) (Table III).
More than half of the patients who had P. aeru­
ginosa isolates with blaIMP genes 6/11 (54.5%) were aged 
between 20 ≤ 30 years old, this was followed by those 
of 30–50 years old 3/11 (27.3%). The lowest percen- 
tage of P. aeruginosa isolates with blaIMP gene 2 (18.2%) 
was recovered from patients above 50 years. On the 
other hand, the highest percentage of patients who 
revealed positive blaSPM gene were aged 20 ≤ 30 years 
old 9/19 (47.4%), followed by those aged > 50 years old 
6/19 (31.6%). 
Table I
Distribution of the 30 patients with MBL producing P. aeruginosa 
isolates according to their gender and age.










No. %No. %No. %
20– < 30 7 58.3 7 38.9 14 46.7
30–50 1  8.3 8 44.4  9 30.0
> 50 4 33.3 3 16.7  7 23.3
χ2 (MCp) 4.570 (0.104)
Site of admission
ICU (n = 126) 21 70.0 χ2 = 0.072 0.789
Ward (n = 49) 9 30.0
Length of hospital stay (days)
≤ 7 (n = 54)  7 23.3 χ2 = 0.961 0.327
> 7 (n = 121) 23 76.7  
Min. – Max. 3.0–39.0
Mean ±SD. 14.97 ± 10.12  Z = 0.519 0.604
Median 12.50   
Associated diseases
DM 22 73.3 χ2 = 18.114* < 0.001*
Cancer 18 60.0 χ2 = 9.052* 0.003*
Related devices
Mechanical ventilator   7 23.3 χ2 = 0.784 0.376
Urinary catheter  7 23.3 χ2 = 8.823* FEp = 0.024*
Readmission (n = 94) 23 76.7 χ2 = 7.672* 0.006*
Antibiotic intake (n = 97) 26 86.7 χ2 = 14.301* < 0.001*
Table II
Distribution of 30 patients with positive MBL producing P. aeruginosa isolates according to risk factors.
χ2: Chi square test; Z: Z for Mann Whitney test; *: Statistically significant at p ≤ 0.05
Frequency of isolation
Risk factors
Patients with MBL producing
P. aeruginosa isolates
(n = 30) Test of sig. P
No. %
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Penicillins
 – Piperacillin 4 13.30 2 6.7 24 80
β-lactam/β-lactamase inhibitor combinations
 – Piperacillin – tazobactam 11 36.7 8 26.7 11 70
Cephems
 – Ceftazidime 2  6.7 10 33.3 18 60
 – Cefepime 5 16.7 4 13.3 21 70
Carbapenems
 – Imipenem 7 23.3 1  2.7 22 73.3
 – Meropenem 4 13.3 6 20 20 66.7
Monobactams
 – Aztreonam 3 10 5 16.7 22 73.3
Aminoglycosides
 – Gentamycin 8 26.7 2  6.7 20 66.7
 – Amikacin 1  3.3 3 10 26 86.7
Fluoroquinolones
 – Ciprofloxacin 5 16.7 1 33.3 24 80
 – Ofloxacin 7 23.3 2  6.7 21 70
Lipopeptides
 – Polymyxin B 26 86.7 0  0.0 4 13.3
Table III









No % No % No %
Site of admission
 ICU 13 68.4 8 72.7 χ2 = 0.062 FEp = 1.000
 Ward  6 31.6 3 27.3
Length of hospital stay (days)
 ≤ 7  5 26.3 2 18.2 χ2 = 0.258 FEp = 0.686
 > 7 14 73.7 9 81.8
 Min. – Max. 4.0 – 37.0  3.0 – 39.0
 Mean ± SD. 14.68 ± 9.84  15.45 ± 11.05  Z = 0.129 0.897
 Median 12.0  14.0
Associated diseases
 DM 15 78.9 7 63.6 0.835 0.417
 Cancer 11 57.9 7 63.6 0.096 1.000
Related devices
 Mechanical ventilator  4 21.1 3 27.3 0.151 1.000
 Urinary catheter   4 21.1 3 27.3 0.151 1.000
Hospital readmission  7 36.7 9 81.8   5.662*   0.017*
Antibiotic intake 10 52.6 8 72.7 1.172 0.442
Table IV
Relation between results of blaIMP gene among 30 patients with MBL producing P. aeruginosa isolates
and their risk factors.
χ2: value for Chi square; MC: Monte Carlo test
FE: Fisher Exact test Z: Z for Mann Whitney test *: Statistically significant at p ≤ 0.05
Risk factors
blaIMP gene
PTest of Sig.Negative (n = 19) Positive (n = 11)
No. % No. %
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P. aeruginosa with positive blaIMP gene were isolated 
from 7 patients with cancer and 7 with diabetes mel-
litus (DM) (63.6% each). In addition, 3 patients were on 
mechanical ventilators (27.3%) and 3 had urinary cath-
eters (Table IV). On the other hand, P. aeruginosa iso-
lates with blaSPM gene were recovered from 5 (26.3.2%) 
patients, who had DM and 7 (36.8%) who suffered from 
cancer (Table V).
Discussion
P. aeruginosa has emerged as a major HCA patho-
gen in both developing and developed countries. This 
organism creates a serious public health disaster result-
ing in an enormous burden of morbidity, mortality 
and high health care cost, especially among high risk 
patients in ICUs (Morales et al., 2012). 
In the present study, 175 (11.1%) P. aeruginosa 
isolates were recovered from a total of 1583 clini-
cal samples that were collected from patients admit-
ted to the AUSH (984 were admitted to ICUs and 
599 wards). A slightly higher percentage was reported 
by Divyashanthi et al. (2015), where 15.2% P. aeruginosa 
isolates were recovered from 788 tested clinical samples. 
In Nepal, Khan et al. (2014), reported that 194 (21.1%) 
P. aeruginosa isolates were identified from 917 collected 
clinical samples from patients with suspected P. aerugi­
nosa infections. A much higher isolation rate (41.5%) 
was recorded by Sedighi et al. (2012), in Iran, where 106 
P. aeruginosa isolates were detected from 255 gathered 
clinical samples. On the other hand, lower percentages 
of isolation were reported in a 3-year study that was 
conducted by Mohanasoundaram (2011) to determine 
the distribution rate and antimicrobial resistance pat-
tern in P. aeruginosa among clinical samples (5%, 6.8% 
and 5% in 2008, 2009 and 2010, respectively). 
One of the main concerns about P. aeruginosa is 
its remarkable ability to rapidly develop antibiotic 
resistance. The wide array of antimicrobial resistance 
mechanisms that have been described for P. aeruginosa 
is impressive and rivals those of other non-fermentative 
Gram-negative pathogens and illustrates the potential 
of this organism to respond swiftly to changes in selec-
tive environmental pressure. In recent years, Egypt has 
been considered among the countries that reported 
high rates of antimicrobial resistance (Zafer et al., 2014) 
In the current study, the susceptibility patterns of 
P. aeruginosa isolates were tested by a panel of anti- 
microbial agents according to CLSI recommendations. 
It was found that P. aeruginosa isolates showed high 
levels of resistance to many antibiotics. One of the 
Site of admission
 ICU 7 63.6 14 73.7 χ2 = 0.335 FEp = 0.687
 Ward 4 36.4  5 26.3
Length of hospital Stay(days)
 ≤ 7 2 18.2  5 26.3 χ2 = 0.258 FEp = 0.686
 > 7 9 81.8 14 73.7
 Min. – Max. 3.0 – 37.0  4.0 – 39.0
 Mean ± SD. 14.18 ± 11.03  15.42 ± 9.84  Z = 0.539 0.590
 Median 11.0  14.0
Associated diseases      
 DM 1  9.0 5 26.3 3.135 FEp = 0.104
 Cancer 0  0.0 7 36.8 1.408 0.235
Related devices 
 Mechanical ventilator 0  0.0  7 36.8   5.286* FEp = 0.029*
 Urinary catheters 2 18.2  5 26.3 0.740 FEp = 0.658
Hospital readmission  4 36.4 15 78.9   5.440*    FEp = 0.047*
Antibiotic intake 3 27.3 13 68.4   4.739* 0.029*
Table V
Relation between results of blaSPM gene among 30 patients with MBL producing P. aeruginosa isolates
and their risk factors.
χ2: value for Chi square; MC: Monte Carlo test
FE: Fisher Exact test Z: Z for Mann Whitney test *: Statistically significant at p ≤ 0.05
Risk factors
blaSPM gene
PTest of Sig.Negative (n = 11) Positive (n = 19)
No. % No. %
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alarming results is the high resistance against carbapen-
ems; where 78.3% of isolates were resistant to imipenem 
and 73.7% were resistant to meropenem. In agreement 
with our results, Diab et al. (2013) revealed a  high 
rate (72%) of imipenem resistance among P. aeru­
ginosa isolates. In the Middle East the occurrence of 
imipenem resistant P. aeruginosa was also recognized. 
In Saudi Arabia, of a total of 350 P. aeruginosa isolates, 
135 (38.57%) were found to be resistant to imipenem 
(Mohamed et al., 2011). Hashemi et al., (2016) reported 
that all their MBL-producing P. aeruginosa isolates were 
resistant to meropenem and imipenem. 
Among 33 European countries participating in the 
European Antimicrobial Resistance Surveillance Sys-
tem (EARSS) in 2007, six countries reported carbap-
enem resistance rates of more than 25% among P. aeru­
ginosa isolates (Souli et al., 2008); the highest rate was 
reported from Greece (51%). Reasons for increased 
antimicrobial resistance in Greece are numerous as 
explained by Miyakis et al. (2011). As Greece has the 
highest antibiotic consumption rate in Europe, both in 
total and in out-patients, population mobility can intro-
duce resistant strains and infrastructure and resources 
for infection control are insufficient. This, along with 
reduced awareness for detection, increases the likeli-
hood of in-hospital spread of multi drug resistant 
organisms (MDROs). Many of these reasons exist in 
our country and can explain the high antimicrobial 
resistance encountered among P. aeruginosa isolates in 
the current study.
During the last decade, emergence and dissemina-
tion of the most prevalent MBL genes such as; blaIMP, 
blaVIM, blaGIM, blaSIM, and the newly identified blaAIM and 
blaNDM have been extensively documented around the 
world. Because of the efficient carbapenemase activ-
ity of the MBL enzymes, they account for up to 40% 
of worldwide imipenem resistant P. aeruginosa. Xavier 
et al. (2010) stated that MBL enzymes increase antimi-
crobial MICs more effectively than does either efflux 
pump over-expression or porin down-regulation alone. 
Unfortunately, screening only carbapenem-resistant 
organisms for these enzymes, as most often performed, 
is suboptimal. With increasing reports of MBLs in 
carbapenem-susceptible isolates, it becomes crucial to 
improve laboratory methods used for detection of what 
is called: hidden MBLs (Ntokou et al., 2008).
In the present study determination of MBL fre-
quency in both carbapenem resistant and susceptible 
P. aeruginosa isolates was done by phenotypic and geno-
typic methods. Accordingly, 30 identified P. aeruginosa 
isolates were selected to cover: the commonly known 
definition of MBL producing P. aeruginosa isolates i.e. 
those that are resistant to all beta lactams but sensitive 
to monobactams (aztreonam), and isolates that showed 
resistance to carbapenems and aztreonam, together 
with isolates that were carbapenem (imipenem) sensi-
tive to exclude hidden MBLs.
The most widely accepted standardized MBL screen-
ing test is the MBL E-test. However, due to the high cost 
and relative unavailability of E-test strips, many clini-
cal microbiology laboratories use alternative screening 
methods, such as double-disk synergy test (DDST) and 
combined disk test (CDT). Although the DDST and the 
CDT assays are simple to perform and cheaper than 
the MBL E-test, they have shown discordant results, 
depending on the employed methodology, β-lactam 
substrates, MBL inhibitors, and bacterial genus tested 
(Picão et al., 2008; Ranjan et al., 2015). In this piece of 
work, all of the 30 (100%) selected P. aeruginosa iso-
lates were found to be MBL producing strains using 
E-test. Similarly Bashir et al. (2011) reported that all 
their thirty isolates were positive for MBL producing 
P. aeruginosa by E-test. 
In the current work, of the 30 identified MBL iso-
lates; the highest percentage was recovered from res-
piratory samples 11 (36.7%), followed by 9 (30%) from 
each of urine and pus and exudate samples, and only 
one isolate (3.3%) was from ear discharge. This is nearly 
in agreement with Zavascki et al. (2006), who found 
that the lung was the most frequent site of nosocomial 
infection (50.3%), followed by urinary tract (20.5%), 
and skin and soft tissue (15.8%). 
Many factors may contribute to the acquisition of 
MBL resistant enzymes. Patients in critical care units 
are likely to have higher probability for these isolates. 
It was found from this study that the highest percent-
age of MBL producing P. aeruginosa isolates was among 
ICU patients (70%). This was in line with Zavascki 
et al. (2006) and Lucena et al. (2014) who found that 
ICUs admission increased the risk for MBL producing 
P. aeru ginosa infections. 
One of the most important parameters for MBL 
acquisition is associated diseases. Of the 30 patients, 
who revealed MBL P. aeruginosa isolates, 22 (73.3%) 
had DM and 18 (60%) suffered from cancer. These 
results were statistically significant (p < 0.001 and 
p = 0.003, respectively). In concordance, Varaiya et al. 
(2008) reported that out of 33 (14.3%) MBL produc-
ing isolates, 24 (72.7%) were diabetic patients, and 
6 (18.1%) were cancer patients. They attributed their 
findings to the associated immune deficiency among 
diabetic patients, and recurrent foot infections being 
good poly-microbial media for a high incidence of 
multidrug-resistant P. aeruginosa. In addition, Vaishali 
et al. (2013) reported that the presence of underlying 
diseases as DM is a significant risk factor in acquisition 
of MBL P. aeruginosa infection.
Other risk factors that were significantly associated 
with the presence of MBL producing P. aeruginosa 
infection in this study were the use of medical devices 
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as mechanical ventilators and urinary catheters (23.3%) 
each, readmission to hospitals (76.7%), and history of 
previous antibiotic intake (86.7%). On the other hand, 
the length of hospital stay for more than 7 days rep-
resented 76.7%, but was not found to be statistically 
significant. Kumar et al. (2011), found that all MBL-
positive patients were exposed to different risk fac-
tors as prolonged hospital stay for more than 8 days, 
cathe terization, previous antibiotic use, and mechanical 
ventilation. In the study done by Vaishali et al. (2013) 
the duration of hospital stay of more than 10 days had 
1.7 times risk of acquisition of MBL P. aeruginosa infec-
tion more than duration of hospital stay of less than or 
equal to10 days.
The occurrence MBL production is not restricted 
to carbapenem resistant strains, but some reports have 
argued about their presence in carbapenem susceptible 
organisms. They might be unrecognized as the MBL 
detection has not been routinely performed in most 
clinical microbiology laboratories (Picão et al., 2012). 
Such organisms often carry hidden MBL genes. As 
a consequence, these isolates will be able to participate 
in horizontal MBL gene transfer with other Gram-
negative pathogens and may contribute significantly 
to MBL related outbreaks. In the present study, of the 
30 identified MBL producing P. aeruginosa isolates, 
7 (23.3%) were imipenem sensitive and 4 (13.3%) were 
sensitive to meropenem. Diab et al. (2013) documented 
that among the studied imipenem susceptible isolates, 
58.3% of which were proved to be MBL producers. 
A much lower percentage was published by Anoar et al. 
(2014) in Iraq, where of the 46 detected MBL produc-
ing isolates, 7 (3.95%) were meropenem sensitive. They 
explained their findings by the possibility that there 
might be hidden MBL genes among isolated strains 
which cannot be diagnosed by phenotypic tests, lead-
ing to the dissemination of these genes in the hospital 
silently among patients even within normal HCWs who 
can act as carriers for MBL genes in future.
In this piece of work, multi drug resistance was 
noticed. MBL producing P. aeruginosa had the high-
est percentage of resistance against amikacin 86.7%, 
followed by piperacillin and ciprofloxacin 80% each. 
In addition, carbapenems showed high percentages 
of resistance; imipenem and meropenem (73.3%, and 
66.7%, respectively). Bhongle et al. (2012) found only 
one isolate sensitive to imipenem, but it was found to be 
positive for MBL, thus indicating that MBL producers 
could show susceptibility to imipenem. These isolates 
can appear to be susceptible to carbapenems though 
they carry carbapenemases, such organisms thus carry 
hidden MBL genes, whereby the microbiologists may 
remain unaware of their presence.
MBL producers are commonly known as those 
organisms that potently hydrolyze all beta-lactam anti-
biotics except aztreonam. In the current study, high 
resistance to monobactams (aztreonam) was detected 
(73.3%), and only 3 (10%) of the isolates were suscep-
tible to aztreonam and conformed to such definition. 
A  lower percentage of aztreonam resistance (45.1%) 
was reported by Zafer et al. (2014). In this study, 86.7% 
of MBL producing P. aeruginosa isolates were suscep-
tible to polymyxin B. This supports the evidence that 
polymyxin B has increasingly become the last viable 
therapeutic option for MDR Pseudomonas infections. 
In accordance with the current results Bashir et al. 
(2011) recorded that MBL producers showed very 
high resistance to all antimicrobials except polymyxin 
B. However, resistance to amikacin (73%) and cipro-
floxacin (55%) was lower when compared to the results 
in the present study (86.7% and 80%, respectively). 
Piperacillin tazobactam was the second most effective 
antibiotic after polymyxin B, where 36.7% of our iso-
lates were sensitive to it. 
Although phenotypic methods are considered to be 
useful and reliable in detecting MBL producers, results 
should be validated and confirmed by genotypic meth-
ods. In the present study, all the 30 (100%) identified 
MBL producing P. aeruginosa isolates by E test were 
further screened for the presence of MBL encoding 
genes (blaIMP, blaSPM, and blaVIM) using conventional 
PCR. blaIMP gene was the most prevalent MBL among 
the isolates accounting for 63.3%, while 36.7% of the 
isolates revealed blaIMP gene and none of the isolates 
had blaVIM genes.
In agreement with the results of this study, Gaspa-
reto et al. (2007) stated that blaSPM gene was the most 
common gene among MBL P. aeruginosa isolates (73%), 
and that no blaVIM gene was detected. Camargo et al. 
(2011) reported that blaSPM gene accounted for 71% of 
positive MBL strains, while blaIMP was detected in 29%. 
On the contrary, blaVIM gene was detected in many 
Egyptian studies. Zafer et al. (2014) demonstrated 
that 58.3% were positive for blaVIM gene, with blaIMP 
gene detected in 2.1% and no blaSPM gene was iden- 
tified. Another study by Diab et al. (2013) revealed 
that 70% were positive for blaVIM, while blaIMP gene 
was not detected.
In the current work, all the 30 P. aeruginosa isolates 
that were identified as MBL producers by the phenotypic 
method E-test, were found to be MBL producers by the 
molecular method PCR; where 19 isolates had MBLSPM 
gene and 11 had blaIMP gene. A lower percentage was 
reported by Doosti et al. (2013); where 36/41 (87.8%) 
of isolates were phenotypically MBL positive, but PCR 
results confirmed presence of MBL genes in only 33/41 
(80%) of isolates. blaIMP producers have been detected 
worldwide: in Europe (Docquier et al., 2003) and in the 
U.S. (Hanson et al., 2006). In the current study, posi-
tive MBL IMP gene producers were more commonly 
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isolated from respiratory samples (36.4%), followed by 
urine and pus and exudate samples (27.3% each). It was 
detected in only one ear discharge sample (9.1%).
In the current work, hospital readmission was found 
to be a significant risk factor for acquiring blaIMP gene, 
where 81.8% of patients were readmitted to the hospital 
within 3 months of the study (p = 0.017).
Among MBL genes, blaSPM has been widely detected 
in Brazil and Switzerland, the dissemination of this 
gene in various regions seems to be caused by a sin-
gle epidemic P. aeruginosa clone (Salabi et al., 2010) In 
the present study, blaSPM gene producers were mostly 
recovered from respiratory samples (47.4%), followed 
by urine (26.3%) and pus and exudate samples (21.1%). 
In line to our data, Zavascki et al. (2006) in southern 
Brazil, described the first nosocomial outbreak of 
P. aeru ginosa producing MBL SPM gene, and noted 
that IMP isolates were highly revealed from respiratory 
samples (43.0%), followed by urine and surgical wound 
samples (33.3% and 5.9%, respectively). While Matos 
et al. (2016) documented that their study was the first 
report describing the detection of the blaSPM-1-like gene 
in northern Brazil.
In the present study, the majority of patients with 
positive blaSPM gene P. aeruginosa isolates were admitted 
to the ICU (73.7%) and 14 (73.7%) had a hospital stay 
duration of more than 7 days. In addition 5 (26.3%) 
had DM and 7 (36.8%) suffered from cancer. It was also 
found that the use of mechanical ventilators was signifi-
cantly associated with positive blaSPM genes (p = 0.029).
Other risk factors that were significantly associated 
with higher rates of positive blaSPM gene were history 
of hospital readmission and antibiotic intake (78.9% 
and 68.4%, respectively). In agreement with the current 
findings, a study to evaluate risk factors for coloniza-
tion or infection due to MDR P. aeruginosa carrying 
blaSPM gene recorded that 50% of patients with positive 
blaSPM gene had Foley’s catheters, 21% were on mechan-
ical ventilation, 78% had been previously hospitalized 
within the preceding year and all patients (100%) had 
taken antibiotics which was the main significant risk 
factor detected (Nouer et al., 2005). Matos et al. (2016) 
reported that 20% (4/20) of their P. aeruginosa isolates 
were positive for the blaSPM-1-like gene, and that MDR 
occurred most frequently among isolates from adults 
who had been hospitalized for an average of 87.1 days, 
where the use of mechanical ventilation and urinary 
catheters were risk factors for infection.
In contrast with other studies (Zafer et al., 2014; 
Mohd et al., 2015) which suggested successful global 
dissemination of blaVIM resistant gene and considered 
it to be of great concern, no blaVIM genes were detected 
in the present work. Zafer et al., in 2014 reported that 
blaVIM gene was detected in 85% of MBL producing 
P. aeruginosa isolates, while Gonçalves et al., (2017) 
reported that among the 157 analyzed P. aeruginosa 
strains, 5.3% were positive for blaVIM gene. 
Ignorance of rational antibiotics prescribing princi-
ples and prolonged clinical use of carbapenems for the 
treatment of MDR P. aeruginosa infections have been 
recognized as the main reasons behind MBL carba-
penamase producing strains. Determination of MBL 
genes in MDR P. aeruginosa gives useful data about 
their epidemiology and risk factors associated with this 
group. Hence, early recognition of MBL pro ducers is 
indispensable and necessitates rigorous infection con-
trol measures (Cantas et al., 2013).
Conclusions
– MBL producing P. aeruginosa isolates were more 
prevalent among patients admitted to the ICUs.
– Polymyxin B was the most effective antimicrobial 
agent against MBL producing P. aeruginosa isolates, 
while amikacin was the least effective one.
– Monobactam (aztreonam) susceptible P. aeruginosa 
isolates were also found to be MBL producers as 
aztreonam resistant ones.
– MBL producers were detected phenotypically by 
E test in both carbapenem susceptible and resistant 
P. aeruginosa isolates. 
– blaSPM was the most commonly detected MBL gene 
in P. aeruginosa isolates.
– blaSPM and blaIMP MBL encoding genes were detected 
in both carbapenem susceptible and resistant P. aeru­
ginosa isolates.
– Associated diseases (DM, cancer), indwelling urinary 
catheters, hospital readmission, and antibiotic intake 
were considered as significant risk factors for MBL 
producing P. aeruginosa infections.
Recommendations
1. Accurate laboratory methods including culture and 
antimicrobial susceptibility testing with routine 
screening for MBL production should be the base for 
proper diagnosis and management of P. aeruginosa 
infections.
2. Early and reliable detection of MBL production in 
P. aeruginosa isolates including monobactam and car-
bapenem susceptible and resistant strains; to permit 
timely institution of effective antimicrobial therapy 
and control dissemination of resistance in hospitals.
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